Opsoclonus-Myoclonus Syndrome in Children: Modern Data
https://doi.org/10.15690/vsp.v24i1.2848
Abstract
Opsoclonus-myoclonus syndrome (Kinsbourne encephalopathy) is a rare neurological disorder characterized by combination of abnormal eye movements (opsoclonus), myoclonus, and cerebellar ataxia. Opsoclonus-myoclonus syndrome develops primarily in children due to immune system pathology associated with infectious or oncological diseases. If this syndrome is comorbid to neuroblastoma, timely diagnosis and complex management determine prognosis for patient’s life and nervous system functions recovery. The variety of factors triggering immunopathological process determines the need for differential diagnosis with wide range of diseases and raising medical community awareness about this rare syndrome. Therapeutic approaches have been being improved due to clinical data accumulation, long-term consequences analysis, and study of pathogenesis. Interaction and succession between neurologists, pediatricians, oncologists, as well as oncological alertness on all stages of patient management are crucial for diagnosis and choosing treatment tactics.
Supporting agencies: Not specified.
About the Authors
Irina F. Fedoseeva
Kemerovo State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Kemerovo
Disclosure of interest:
Not declared.
Alexey V. Goncharenko
Kemerovo State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Kemerovo
Disclosure of interest:
Not declared.
Tatyana V. Poponnikova
Kemerovo State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Kemerovo
Disclosure of interest:
Not declared.
Vladimir A. Goncharenko
Kemerovo State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Kemerovo
Disclosure of interest:
Not declared.
References
1. Bhatia P, Heim J, Cornejo P, et al. Opsoclonus-myoclonusataxia syndrome in children. J Neurol. 2022;269(2):750–757. doi: https://doi.org/10.1007/s00415-021-10536-3
2. Burlakova NS, Mikadze YV, Fedorova YN, et al. The clinical and psychological features of mental development in children with opsoclonus-myoclonus syndrome. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):52–56. (In Russ). doi: https://doi.org/10.14412/2074-2711-2018-2-52-56]
3. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry. 1962;25(3):271–276. doi: https://doi.org/10.1136/jnnp.25.3.271
4. Jimenez Giraldo S, Michaelis M, Kerr L, et al. Inaugural Patient-Reported Registry of Pediatric Opsoclonus-MyoclonusAtaxia Syndrome: Presentation, Diagnosis, and Treatment of 194 Patients. Pediatr Neurol. 2024;158:128–134. doi: https://doi.org/10.1016/j.pediatrneurol.2024.06.007
5. Aktekin EH, Gezer HÖ, Yazıcı N, et al. Five Years Follow-up of Opsoclonus-Myoclonus-Ataxia Syndrome-Associated Neurogenic Tumors in Children. Neuropediatrics. 2024;55(1):57–62. doi: https://doi.org/10.1055/s-0043-1768143
6. Rumiantseva KA, Polushin AYu, Abduloeva NKh, et al. Opsoclonus-myoclonus-ataxia syndrome as a complication of pembrolizumab treatment in an adult patient (a case report and literature review). Epilepsy and paroxysmal conditions. 2023;15(1):26–35. (In Russ). doi: https://doi.org/10.17749/2077-8333/epi.par.con.2023.131]
7. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonusmyoclonus syndrome. J Pediatr Oncol Nurs. 2005;22(1):8–19. doi: https://doi.org/10.1177/1043454204272560
8. Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/ opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol. 2010;14(2):156–161. doi: https://doi.org/10.1016/j.ejpn.2009.03.002
9. Hasegawa S, Matsushige T, Kajimoto M, et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev. 2015;37(7):656–660. doi: https://doi.org/10.1016/j.braindev.2014.10.010
10. Rossor T, Yeh EA, Khakoo Y, et al. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1153. doi: https://doi.org/10.1212/NXI.0000000000001153
11. Malevich OB, Il’ina ES, Homyakova SP, et al. Opsoclonus–myoclonus syndrome in children with neurogenic tumors: a view of a neurologist. Pediatria. Journal n.a. G.N. Speransky. 2019;98(2):221–226. (In Russ). https://doi.org/10.24110/0031-403X-2019-98-2-221-226]
12. Kachanov DY, Shamanskaya TV, Il’ina ES, et al. Sympathetic Nervous System Tumors in Children with Opsoclonus-Myoclonus Syndrome. Onkopediatria. 2016;3(3):228–239. (In Russ). doi: https://doi.org/10.15690/onco.v3i3.1602]
13. Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology (“Tumor” vs. “No tumor”) in a cohort of 356 US children. Pediatr Blood Cancer. 2018;65(8):e27097. doi: https://doi.org/10.1002/pbc.27097
14. Anand S, Agarwala S, Jain V, et al. Neuroblastoma with Opsoclonus-Myoclonus-Ataxia Syndrome: Role of Chemotherapy in the Management: Experience From a Tertiary Care Center in a Resource-limited Setting. J Pediatr Hematol Oncol. 2021;43(7): e924–e929. doi: https://doi.org/10.1097/MPH.0000000000002131
15. Kumar R, Vankadari K, Mittal BR, et al. Diagnostic values of 68Ga-labelled DOTANOC PET/CT imaging in pediatric patients presenting with paraneoplastic opsoclonus myoclonus ataxia syndrome. Eur Radiol. 2021;31(7):4587–4594. doi: https://doi.org/10.1007/s00330-020-07587-x
16. Zhou J, Zhuo XW, Jin M, et al. Clinical and prognostic analysis of opsoclonus-myoclonus-ataxia syndrome in children. Zhonghua Er Ke Za Zhi. 2024;62(3):256–261. doi: https://doi.org/10.3760/cma.j.cn112140-20230911-00174
17. Saini L, Dhawan SR, Madaan P, et al. Infection-Associated Opsoclonus: A Retrospective Case Record Analysis and Review of Literature. J Child Neurol. 2020;35(7):480–484. doi: https://doi.org/10.1177/0883073820911327
18. Alekseeva TM, Topuzova MP, Skripchenko NV, et al. Virus-induced opsoclonusmyoclonus syndrome during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(5):93–99. (In Russ). doi: https://doi.org/10.17116/jnevro202012005193]
19. Adamaszek M, Langner S, Mehrholz J, Heiinrich A. OpsoclonusMyoclonus-Ataxia Syndrome Due to Covid-19. Cerebellum. 2024;23(3):1245–1248. doi: https://doi.org/10.1007/s12311-023-01610-36
20. Cannilla H, Messe M, Girardin F, et al. Drug- and Toxin-Induced Opsoclonus — a Systematized Review, including a Case Report on Amantadine-Induced Opsoclonus in Multiple System Atrophy. Tremor Other Hyperkinet Mov (N Y). 2024;14:23. doi: https://doi.org/10.5334/tohm.832
21. Hsu M, Tejani I, Shah N, et al. Review of OpsoclonusMyoclonus Ataxia Syndrome in Pediatric Patients. Children (Basel). 2024;11(3):367. doi: https://doi.org/10.3390/children11030367
22. Ghia T, Kanhangad M, Alessandri AJ, et al. Opsoclonus-Myoclonus Syndrome, Neuroblastoma, and Insulin-Dependent Diabetes Mellitus in a Child: A Unique Patient. Pediatr Neurol. 2016;55:68–70. doi: https://doi.org/10.1016/j.pediatrneurol.2015.09.021
23. Alburaiky S, Dale RC, Crow YJ, et al. Opsoclonus-myoclonus in Aicardi-Goutières syndrome. Dev Med Child Neurol. 2021;63(12):1483–1486. doi: https://doi.org/10.1111/dmcn.14969
24. Almudhry M, Wagner MW, Longoni G, et al. Brain Volumes in Opsoclonus-Myoclonus Ataxia Syndrome: A Longitudinal Study. J Child Neurol. 2024;39(3-4):129–134. doi: https://doi.org/10.1177/08830738241240181
25. Chekroud AM, Anand G, Yong J, et al. Altered functional brain connectivity in children and young people with opsoclonusmyoclonus syndrome. Dev Med Child Neurol. 2017;59(1):98–104. doi: https://doi.org/10.1111/dmcn.13262
26. Santoro JD, Kerr LM, Codden R, et al. Increased Prevalence of Familial Autoimmune Disease in Children with Opsoclonus-Myoclonus Syndrome. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1079. doi: https://doi.org/10.1212/NXI.0000000000001079
27. Mitoma H, Manto M. Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms. J Neurol. 2024;271(10):7046–7053. doi: https://doi.org/10.1007/s00415-024-12596-7
28. Rossi M, van der Veen S, Merello M, et al. Myoclonus-Ataxia Syndromes: A Diagnostic Approach. Mov Disord Clin Pract. 2020;8(1):9–24. doi: https://doi.org/10.1002/mdc3.131067
29. Cantarín-Extremera V, Jiménez-Legido M, Aguilera-Albesa S, et al. Opsoclonus-myoclonus syndrome: Clinical characteristics, therapeutic considerations, and prognostic factors in a Spanish paediatric cohort. Neurologia (Engl Ed). 2023;38(2):93–105. doi: https://doi.org/10.1016/j.nrl.2020.04.025
30. Du H, Cai W. Opsoclonus-myoclonus syndrome associated with neuroblastoma: Insights into antitumor immunity. Pediatr Blood Cancer. 2022;69(11):e29949. doi: https://doi.org/10.1002/pbc.29949
31. Zar T, Tschernatsch M, Hero B, et al. Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome. J Pediatr Hematol Oncol. 2021;43(2):e176–e179. doi: https://doi.org/10.1097/MPH.0000000000001953
32. Noguchi K, Ikawa Y, Takenaka M, et al. Presence of identical B-cell clone in both cerebrospinal fluid and tumor tissue in a patient with opsoclonus-myoclonus syndrome associated with neuroblastoma. Pediatr Hematol Oncol. 2023;40(4):363–370. doi: https://doi.org/10.1080/08880018.2022.2109784
33. Ding X, Yang W, Ren Q, et al. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma. J Neuroinflammation. 2020;17(1):190. doi: https://doi.org/10.1186/s12974-020-01839-9
34. Sun Q, Wang Y, Xie Y, et al. Long-term neurological outcomes of children with neuroblastoma with opsoclonus-myoclonus syndrome. Transl Pediatr. 2022;11(3):368–374. doi: https://doi.org/10.21037/tp-21-519
35. Rosenberg MI, Greenstein E, Buchkovich M, et al. Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma. Cell Rep. 2023;42(8):112879. doi: https://doi.org/10.1016/j.celrep.2023.112879
36. Hero B, Clement N, Øra I, et al. Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. J Pediatr Hematol Oncol. 2018;40(2):93–98. doi: https://doi.org/10.1097/MPH.0000000000000976
37. Pranzatelli MR, Tate ED. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome. Brain Dev. 2016;38(5):439–448. doi: https://doi.org/10.1016/j.braindev.2015.11.007
38. Grossman SN, Rucker JC. Opsoclonus and ocular flutter: evaluation and management. Curr Opin Ophthalmol. 2023;34(6):465–469. doi: https://doi.org/10.1097/ICU.0000000000000998
39. Strupp ML, Straumann D, Helmchen C. Central Ocular Motor Disorders: Clinical and Topographic Anatomical Diagnosis, Syndromes and Underlying Diseases. Klin Monbl Augenheilkd. 2021; 238(11):1197–1211. doi: https://doi.org/10.1055/a-1654-0632
40. Helmchen C, Heide W, Strupp ML, Straumann D. Update on central oculomotor disorders and nystagmus. Laryngorhinootologie. 2024;103(6):413–421. doi: https://doi.org/10.1055/a-2192-7319
41. Storz C, Bares R, Ebinger M, et al. Diagnostic value of wholebody MRI in Opsoclonus-myoclonus syndrome: a clinical case series (3 case reports). BMC Med Imaging. 2019;19(1):70. doi: https://doi.org/10.1186/s12880-019-0372-y
42. Urtiaga Valle S, Souvannanorath S, Leboucq N, et al. Monocentric retrospective clinical outcome in a group of 13 patients with opsoclonus myoclonus syndrome, proposal of diagnostic algorithm and review of the literature. Eur J Paediatr Neurol. 2022;40:18–27. doi: https://doi.org/10.1016/j.ejpn.2022.07.002
43. Feng L, Yang S, Lin Y, et al. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma. Pediatr Radiol. 2024;54(6):954–964. doi: https://doi.org/10.1007/s00247-024-05921-9
44. Segal JE, Ritchey AK, Tersak J, et al. Pediatrician’s Approach to Recognizing 44 Neuroblastoma With Opsoclonus-MyoclonusAtaxia Syndrome. Clin Pediatr (Phila). 2023;62(8):820–823. doi: https://doi.org/10.1177/00099228221147407
45. Meira AT, de Moraes MPM, Ferreira MG, et al. Immunemediated ataxias: Guide to clinicians. Parkinsonism Relat Disord. 2023;117:105861. doi: https://doi.org/10.1016/j.parkreldis.2023.105861
46. Auconi M, Papetti L, Ruscitto C, et al. Opsoclonus-Myoclonus Syndrome in Children and Adolescents: A Therapeutic Challenge. Children (Basel). 2021;8(11):965. doi: https://doi.org/10.3390/children8110965
47. Kerstens J, Titulaer MJ. Overview of treatment strategies in paraneoplastic neurological syndromes. Handb Clin Neurol. 2024;200:97–112. doi: https://doi.org/10.1016/B978-0-12-823912-4.00015-3
48. de Alarcon PA, Matthay KK, London WB, et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018;2(1):25–34. doi: https://doi.org/10.1016/S2352-4642(17)30130-X
49. Pranzatelli MR, Allison TJ, Tate ED. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study. Eur J Paediatr Neurol. 2018;22(4):586–594. doi: https://doi.org/10.1016/j.ejpn.2018.02.009
50. Santiago JA, Babico M, Stitt G, et al. Low-dose intrathecal rituximab is a safe and potentially effective treatment for pediatric neuroimmunologic disorders. J Neuroimmunol. 2021;359:577687. doi: https://doi.org/10.1016/j.jneuroim.2021.577687
51. Johnston DL, Murray S, Irwin MS, et al. Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome. Pediatr Blood Cancer. 2018;65(8):e27110. doi: https://doi.org/10.1002/pbc.27110
52. Zouari R, Bouchaala W, Nsir SB, et al. Opsoclonus myoclonus induced by lamotrigine toxicity. Seizure. 2021;91:247–250. doi: https://doi.org/10.1016/j.seizure.2021.06
53. Miyoshi H, Nakamura R, Yamaga A, et al. Transient symptomatic worsening by atropine in opsoclonus-myoclonus syndrome. Pediatr Int. 2017;59(1):97–98. doi: https://doi.org/10.1111/ped.13180
54. Yıldırım M, Öncel İ, Bektaş Ö, et al. Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome. Eur J Paediatr Neurol. 2022;41:19–26. doi: https://doi.org/10.1016/j.ejpn.2022.09.002
55. Kumar P, Willard VW, Embry L, et al. Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonusmyoclonus-ataxia-syndrome: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2024;71(7):e31039. doi: https://doi.org/10.1002/pbc.31039
56. Goh EL, Scarff K, Satariano S, et al. Evolving Cognitive Dysfunction in Children with Neurologically Stable OpsoclonusMyoclonus Syndrome. Children (Basel). 2020;7(9):103. doi: https://doi.org/10.3390/children7090103
57. Sheridan A, Kapur K, Pinard F, et al. IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study. Dev Med Child Neurol. 2020;62(12):1444–1449. doi: https://doi.org/10.1111/dmcn.14628
58. Kachanov DYu, Shamanskaya TV, Malevich OB, Varfolomeeva SR. Opsoclonus-myoclonus syndrome and neuroblastoma (a review of literature). Russian Journal of Pediatric Hematology and Oncology. 2014;1(1):62–69. (In Russ). doi: https://doi.org/10.17650/2311-1267-2014-0-1-62-69]
59. Bacchus MK, Anderson DS, Berko ER, et al. Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments. J Pediatr Hematol Oncol. 2023;45(3):152–154. doi: https://doi.org/10.1097/MPH.0000000000002643
Review
For citations:
Fedoseeva I.F., Goncharenko A.V., Poponnikova T.V., Goncharenko V.A. Opsoclonus-Myoclonus Syndrome in Children: Modern Data. Current Pediatrics. 2025;24(1):6–12. (In Russ.) https://doi.org/10.15690/vsp.v24i1.2848
Views:
689
Email this article 
